Alcon, an American Swiss medical company, has inked an agreement to acquire Kala Pharmaceuticals’ EYSUVIS® 0.25% eye drops. The acquisition will accompany Alcon’s existing portfolio in the fast-expanding dry eye category.
EYSUVIS will be complementing the Systane portfolio of eye drops of Alcon which includes the recently unveiled Systane Preservative-Free formulations, which are now available in a multi-dose, convenient bottle.
It was authorized by the U.S. FDA (Food & Drug Administration) in January 2021 as the first-and-only corticosteroid designated for two weeks of treatment of the signs & symptoms of dry eye disease.
Although the Systane portfolio is used for the management of dry eye symptoms, EYSUVIS will be offering ECPs (Eye Care Professionals) an option for short-term treatment to lessen dry eye cases.
As per research by Alcon, around 30 million people in the US suffer from dry eye. About 20 to 25% of dry eye patients undergo serious episodes of the dry eye normally two times per year. EYSUVIS, could be given by ECPs during such incidents of acute dry eye.
Commenting on the move, Sergio Duplan, President of Alcon (North America), said that the firm is pleased to add EYSUVIS to its growing pharmaceutical portfolio. EYSUVIS is an ideal fit for the firm’s newly formed ophthalmic eye drop sales force in the United States.
With the strong knowledge of Alcon in commercial execution and market access, the firm is well-positioned to prepare the market for treating acute dry eyes.
Apart from EYSUVIS, under this agreement, Alcon will be acquiring INVELTYS ® (loteprednol etabonate suspension) 1%, the only corticosteroid that can be used twice a day to treat post-operative inflammation pain following ocular surgery.
Source Credit - https://www.businesswire.com/news/home/20220521005008/en/Alcon-to-Acquire-EYSUVIS-Adding-to-Its-Ophthalmic-Eye-Drop-Portfolio